CA
NZ
UK
AU
IND
US
The ruling matters beyond the immediate legal question. Collaboration agreements between gene-editing companies frequently define exclusivity boundaries around specific disease targets or therapeutic modalities, and disputes over where those boundaries lie can create prolonged uncertainty for programs caught in the middle. With the arbitration …
PM647 represents an application of prime editing — a precision gene-correction technology capable of directly rewriting disease-causing mutations rather than merely silencing or replacing genes — aimed at the SERPINA1 mutation responsible for Alpha-1 Antitrypsin Deficiency. The condition results in insufficient production of a …
Both 4-1BB and OX40 are costimulatory receptors found on immune cells, and each has attracted substantial pharmaceutical industry interest as a potential lever for enhancing anti-tumor immune responses when engaged appropriately. Bispecific antibodies that target both receptors concurrently aim to capture complementary biological effects …
Third-line NSCLC represents a particularly challenging treatment setting, as patients at this stage have typically already progressed through both chemotherapy and first-line immunotherapy or targeted treatment, leaving oncologists with a narrowing set of options and generally more modest expectations for disease control relative to …
Third-line NSCLC represents a particularly challenging treatment setting, as patients at this stage have typically already progressed through both chemotherapy and first-line immunotherapy or targeted treatment, leaving oncologists with a narrowing set of options and generally more modest expectations for disease control relative to …
The regulatory clarity comes on the heels of earlier Phase 2a data, presented in abstract form at the ARVO ophthalmology conference, that showed meaningful separation from placebo on patient-reported quality-of-life measures. Specifically, patients receiving urcosimod reported a mean change from baseline of −4.5 in …
ZORYVE, a topical phosphodiesterase-4 inhibitor, has already secured approvals in older age groups and related inflammatory skin conditions, giving Arcutis an established commercial and safety track record to lean on as it pursues this pediatric expansion. Extending the label to infants would meaningfully broaden …
Non-muscle invasive bladder cancer represents the majority of newly diagnosed bladder cancer cases and is characterized by a persistently high recurrence rate even after initial treatment, creating durable demand for new therapeutic options that can either reduce recurrence or provide effective salvage therapy for …
Valuing a clinical-stage or pre-commercial biotech ahead of a binary regulatory decision is an inherently probabilistic exercise, and Immunome's current market capitalization suggests investors are already assigning a fairly constructive probability to eventual approval, rather than treating the stock as a coin-flip proposition. That …
Beyond the imaging endpoint, the trial produced functional signals that investors found equally persuasive. Patients recorded a 34% mean increase in upper-limb effort alongside a 38% reduction in creatine kinase, a blood marker of muscle damage, while overall strength remained stable throughout the observation …
Please wait processing your request...